Lexeo Therapeutics, Inc. Common Stock (LXEO)
Lexeo Therapeutics, Inc. is a biotechnology company focused on developing therapies for rare neurodegenerative diseases. The company leverages gene therapy and other advanced modalities to address unmet medical needs, aiming to improve quality of life for patients with limited treatment options.
Company News
Lexeo Therapeutics has priced a public offering and private placement, raising approximately $135 million by selling 15,625,000 shares at $8.00 per share and pre-funded warrants to Balyasny Asset Management.
The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.
Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
This article discusses the upcoming events in the financial world, including the Federal Reserve meeting, corporate earnings, IPOs, and investor events.
RBC Capital has decided to maintain its Outperform rating of Lexeo Therapeutics (NASDAQ:LXEO) and raise its price target from $22.00 to $24.00. Shares of Lexeo Therapeutics are trading up 7.11% over the last 24 hours, at $15.52 per share. A move to $24.00 would account for a 54.64% increase from the current share price. About Lexeo Therapeutics L...